Gossamer Bio market cap GOSS
Share price times shares outstanding: what the whole company sells for, since 2019.
- Today, Nov 2, 2026
- $57.7M
- Highest close in our data
- $1.7B
- Dec 2019
Gossamer Bio is worth $57.7M at the close on Nov 2, 2026, at $9.45 a share.
That is down 89% over the last year and down 94% over five years.
Its highest close in our data was $1.7B in Dec 2019.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $57.7M | $31.9M | $666.6M | −92% |
| 2025 | $747.6M | $181.8M | $833.2M | +286% |
| 2024 | $193.7M | $117.6M | $329.4M | −6% |
| 2023 | $205.7M | $91.3M | $263.6M | +0% |
| 2022 | $205M | $179.5M | $1.3B | −76% |
| 2021 | $864.8M | $554.9M | $1.1B | +18% |
| 2020 | $734.2M | $627.4M | $1.1B | −29% |
| 2019 | $1B | $977.7M | $1.7B | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Gossamer Bio's size, closest first, today.
| Company | Market cap |
|---|---|
| GOSSGossamer Bio | $57.7M |
| SPROSpero Therapeutics | $60.6M |
| LFVNLifevantage | $73.5M |
| ATNMActinium Pharmaceuticals | $45M |
| NATRNatures Sunshine Products | $211.5M |
| CRMDCorMedix | $420.1M |
| ARVNArvinas | $491.7M |
| PBYIPuma Biotechnology | $525.5M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| Peer median | $315.8M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Gossamer Bio
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.